Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study

Study with novel trial design did not meet primary endpoint

INDIANAPOLIS, Feb. 10, 2020 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) today announced that the analysis performed by Washington University School of Medici... Biopharmaceuticals, Neurology Eli Lilly, solanezumab, Alzheimer's disease

Source: HSMN NewsFeed - February 10, 2020 Category: Pharmaceuticals Source Type: news